MODELING NATURAL HISTORY AND COST-EFFECTIVENESS OF GENE-AGNOSTIC TREATMENT IN RETINITIS PIGMENTOSA
A gene-agnostic treatment for RP with drug price of $1.5 million (both eyes) may be cost-effective for most types of RP, particularly with earlier initiation. These findings can inform clinical, economic, and health policy decisions, potentially supporting early intervention strategies and resource allocation for novel RP treatments.
Authors
- Patrick W. Sullivan (ORCID: https://orcid.org/0009-0003-2783-7177)
- Sandeep Grover (ORCID: https://orcid.org/0000-0002-3771-7510)
- Thiran Jayasundera (ORCID: https://orcid.org/0000-0003-4895-4818)
- Albert I. Wertheimer (ORCID: https://orcid.org/0000-0002-0098-5677)
Institutions
- W.K. Kellogg Foundation (US)
- Touro College (US)
- Nova Southeastern University (US)
- University of Michigan (US)
- University of Florida (US)
- Florida College (US)
Publication Details
- Journal
- Retina
- Published
- 2025-12-09
- DOI
- https://doi.org/10.1097/iae.0000000000004735
- Primary Topic
- Retinal Development and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00